Introduction MENCEVAX powder and solvent for solution for injection Meningococcal polysaccharide vaccine for serogroups A, C, Y, W135 Powder and solvent in prefilled syringe with needles B/1 (CIP: 385 883-5) Powder and solvent in vials B/1 (CIP: 385 885-8) Powder and solvent in 10-dose vials B/50 (CIP: 385 888-7) Posted on Mar 14 2011 Active substance (DCI) serogroup A Neisseria meningitidis serogroup C Neisseria meningitidis serogroup Y Neisseria meningitidis serogroup W135 Neisseria meningitidis MALADIES INFECTIEUSES – NOUVEAU MEDICAMENT Progrès thérapeutique majeur dans la prévention de la maladie méningococcique invasive due aux méningocoques des groupes Y et W135 Ce nouveau vaccin est indiqué dans l’immunisation active des adultes, adolescents et enfants de plus de 2 ans contre la maladie méningococcique invasive due aux méningocoques des groupes A, C, W135 et Y.Il est le seul vaccin disponible dans la prévention de la maladie éningococcique invasive due aux méningocoques des groupes Y et W135.MENCEVAX doit être utilisé selon les recommandations du Haut Conseil de la santé publique.Pour en savoir plus, téléchargez la synthèse ou l'avis complet ci-dessous. ATC Code J07AH04 Laboratory / Manufacturer GLAXOSMITHKLINE MENCEVAX powder and solvent for solution for injection Meningococcal polysaccharide vaccine for serogroups A, C, Y, W135 Powder and solvent in prefilled syringe with needles B/1 (CIP: 385 883-5) Powder and solvent in vials B/1 (CIP: 385 885-8) Powder and solvent in 10-dose vials B/50 (CIP: 385 888-7) Posted on Mar 14 2011
Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
Langue
English
Extrait
The legally binding text is the original French version
TRANSPARENCY COMMITTEE OPINION 4 March 2009 MENCEVAX powder and solvent for solution for injection Meningococcal polysaccharide vaccine for serogroups A, C, Y, W135Powder and solvent in prefilled syringe with needles B/1 (CIP: 385 883-5) Powder and solvent in vials B/1 (CIP: 385 885-8) Powder and solvent in 10-dose vials B/50 (CIP: 385 888-7) Applicant: GLAXOSMITHKLINE Serogroup ANeisseria meningitidisSerogroup CNeisseria meningitidisSerogroup YNeisseria meningitidisSerogroup W135Neisseria meningitidisList I ATC Classification: J07AH04 Date of Marketing Authorisation (MA): 19 May 2008 Procedure: Mutual Recognition Reason for request: Inclusion on the list of medicines approved for use by hospitals. Medical, Economic and Public Health Assessment Division